Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In EDAP TMS SA (EDAP) To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in EDAP TMS SA (“EDAP” or the “Company”) (NasdaqGM: EDAP) of the October 3, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against EDAP and certain executives.
A complaint has been filed in the United Stated District Court of the Southern District of New York on behalf of all persons who purchased EDAP securities between February 1, 2013 and July 30, 2014, inclusive (the “Class Period”).
The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.
Specifically, the action alleges that during the Class Period, Company made false and/or misleading statements and/or failed to disclose that: (i) EDAP exaggerated the efficacy and safety of its Ablatherm trials; (ii) the occurrence of the adverse events in its trials were understated; and (iii) as a result, the Company’s statements were materially false and misleading at all relevant times.
On July 28, 2014, FDA staff report stated its concerns about EDAP’s adequacy of their test trial methods. The staff report also revealed high rates of adverse events associated with the drug, which the Company had not properly disclosed. As a result of this report, EDAP was downgraded from “Outperform” to “Market Perform” at Northland Securities by equity analyst Suraj Kalia.
On this news, the price of EDAP stock declined by $1.23, or over 25%, to close at $3.65 on July 28, 2014.
On July 30, 2014, EDAP filed a Form 6-K with SEC and issued a press release on its discussion with the U.S. Food and Drug Administration (“FDA”) Advisory Committee Meeting on Ablatherm. FDA’s Gastroenterology and Urology Devices Panel (“GUDP”) voted 3 yes, 5 no with one abstention regarding the safety of the drug, and 8 no with 1 abstention on the question of the risk/benefit ratio of the use of Ablatherm-HIFU device for treatment of prostate cancer.
Following this news, the price of EDAP stock declined by $1.50, or over 44%, to close at $1.92 on July 31, 2014.
If you invested in EDAP stock or options between February 1, 2013 and July 30, 2014 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding EDAP’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.